2022

Merger of GenoBio Corp. and ExoTDX Corp

GenoCTC V5 development completed

2021

ExoTDX Corp. provides Exo-FAST to Harvard Medical School

2020

Publication - An Immune-Magnetophoretic Device for the Selective
and Precise Enrichment of Circulating Tumor Cells from Whole
Blood (Micromachines (Basel). 2020 May 30;11(6):560

2019

GenoCTC Version3 Item approval (Class 1)

2018

Approval of EpCAM-positive cell separation kit (Class 2)

GMP certification for in vitro diagnostic medical device reagent
production (Class 2)

Copyright agreement with Gencurix for products and services in Asia

2017

GenoCTC Version2 FCC, CE certified

Genobio-Deepbio integrated prostate cancer diagnosis system development agreement

2016

Ministry of Trade, Industry and Energy's selection of commercialization-
linked technology development

Venture Business Certification (No. 2020107264)

Medical device production GMP certification (Class 1)

Signed a strategic alliance with Genobio-Genocurix for "liquid biopsy"

2015

Selected as the 3rd general manager of the anticancer drug companion diagnosis project (source technology

2014

Established Genobio with the goal of developing a circulating tumor
cell isolation system